Navigation Links
Focal Healthcare’s Fusion Bx 2.0 Targeted Prostate Biopsy Solution Receives CE Mark
Date:11/5/2019

Focal Healthcare, an innovator of image-guided prostate cancer technology, announced it has received CE Mark for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining information from multiparametric MRI (mpMRI) with a semi-robotic arm and user-friendly interface, the Fusion Bx 2.0 will give urologists across Europe the ability to perform targeted transrectal and transperineal prostate biopsies.

Earlier this year, both the European Association of Urology (EAU) and the National Institute for Health and Care Excellence (NICE) released updated guidelines that recommend the use of mpMRI prior to biopsy, followed by a targeted biopsy when the MRI is positive. This diagnostic pathway reduces the number of biopsies while increasing the likelihood of finding significant cancers. These recommendations highlight the important role played by MRI/Ultrasound fusion technology and the need for an accurate and accessible device such as the Fusion Bx 2.0.

“We are excited to receive the CE Mark as it greatly expands the market for our Fusion Bx,” said Chicuong La, CEO of Focal Healthcare. “The results from last year’s PRECISION trial has changed the way in which prostate cancer is being diagnosed in Europe. Now urologists throughout the EU will have access to our Fusion Bx – providing them with a targeted biopsy system that is accurate, and simple to learn and use. This will make it easier for clinics and hospitals of all sizes to adopt the new guidelines.”

Focal Healthcare’s Fusion Bx 2.0 provides urologists with the ability to perform both transrectal and transperineal biopsies using a simple and intuitive interface. Fusion Bx 2.0 features:

  • A semi-robotic arm that keeps the probe steady to ensure consistent pressure on the prostate, limiting movement and deformation, thereby leading to increased accuracy
  • A 3D model that allows the urologist to visualize the prostate and MRI targets in real-time to guide the biopsy needle to the regions of interest
  • Automatic motion compensation which adjusts for patient movement to maintain image registration, allowing procedures to continue uninterrupted
  • A step-by-step guided workflow combined with semi-automatic segmentation that enables urologists to perform procedures in less time and with minimal training

Fusion Bx 2.0 will be available to European physicians through distribution. Fusion Bx 2.0 is also cleared for sale in Canada, USA and Taiwan. For more information, contact Focal Healthcare at sales@focalhealthcare.com.

About Focal Healthcare Inc.

Focal Healthcare is a Canadian-based medical device company committed to improving the lives of prostate cancer patients and their families through technical innovation. By developing imaging tools that emphasize accuracy, efficiency and accessibility, Focal Healthcare strives to advance prostate cancer diagnosis and management in clinics and hospitals of all sizes. Focal Healthcare designs and manufactures all its products at its headquarters in Toronto, Canada.

Read the full story at https://www.prweb.com/releases/focal_healthcares_fusion_bx_2_0_targeted_prostate_biopsy_solution_receives_ce_mark/prweb16657872.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Mann Eye Institute Offers Whats Been Called the "Biggest Advancement in Reading Vision Since the Bifocal"
2. ImageXpress Micro Confocal High-Content Imaging System Expands the Boundaries of Research
3. AMA Recognized as the Focal Point for Aero-modeling
4. L3 Healthcare’s Clinical Trials Division Becomes Certified Designer for iMedNet eClinical and Electronic Data Management Software
5. Dr. Alexios Apazidis Completes Successful Discectomy & Fusion Surgery Using SpineFrontier's A-CIFT SoloFuse™ Less Exposure Surgery Technology
6. Alevio® completes the 500th case with SiCure™ Sacroiliac Fusion System
7. FACIT-Seeded Fusion Pharmaceuticals Closes US$25M Series A Led by Johnson & Johnson Innovation
8. Interbody-Fusion Outcomes May Be Improved by Use of Invibio's PEEK-OPTIMA™ HA Enhanced Polymer
9. Vertera Spines COHERE Fusion Device Wins Award For Best Spine Technologies for 2016
10. Newly Published Spine Surgery Study Shows Cervical Total Disc Replacement To Provide Better Results Than Fusion in Outpatient Setting
11. Amarantus Announces Capital Infusion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
(Date:7/7/2020)... ... 2020 , ... R3 International is now offering stem cell therapy for Alzheimers ... Depending on the patient's condition, treatment may be offered IV, intrathecal or with a ... of Alzheimers dementia, and the incidence continues to increase as individuals live longer. There ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... the launch of a new clinical diagnostics immuno-oncology service, TissueInsight . ... (TME). , “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and ...
(Date:6/28/2020)... ... June 26, 2020 , ... The Security Industry ... its strong opposition to the recently introduced bicameral Facial Recognition and Biometric ... most federal use of nearly all biometric and related image analytics technologies, incorrectly ...
Breaking Biology Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... ... that an extensive third-party assessment of the company’s security practices has been completed. ... federal security regulations. The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them ...
(Date:8/26/2020)... ... August 25, 2020 , ... Catalent, ... drugs, biologics, cell and gene therapies, and consumer health products, today announced that ... Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020. ...
(Date:8/21/2020)... , ... August 18, 2020 , ... ... cell therapy, today announced that the U.S. Food and Drug Administration (FDA) has ... lead asset, SBI-101, for the treatment of severe COVID-19. Approval of this IND ...
Breaking Biology News(10 mins):